212 related articles for article (PubMed ID: 19466965)
21. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
22. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
[TBL] [Abstract][Full Text] [Related]
23. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
24. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
25. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
Ansell SM
Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
[TBL] [Abstract][Full Text] [Related]
27. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
Pinter-Brown LC
Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
[TBL] [Abstract][Full Text] [Related]
28. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R
Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
30. SGN-30 (Seattle genetics).
Schnell R; Borchmann P
Curr Opin Mol Ther; 2006 Apr; 8(2):164-72. PubMed ID: 16610770
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
[TBL] [Abstract][Full Text] [Related]
32. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
33. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
36. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
38. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
39. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.
Dürkop H; Hirsch B; Hahn C; Foss HD; Stein H
J Pathol; 2003 Jun; 200(2):229-39. PubMed ID: 12754742
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with daclizumab of refractory anaplastic lymphoma.
Costa V; Oliva T; Norton L
Pediatr Blood Cancer; 2009 Dec; 53(6):1130-1. PubMed ID: 19598219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
